CRISPR Therapeutics provided a business update for the fourth quarter and full year ended December 31, 2024, highlighting continued momentum for the CASGEVY launch. As of the end of 2024, more than 50 authorized treatment centers (ATCs) were activated globally, and over 50 patients had undergone cell collection across all regions. The company anticipates significant growth in new patient collection initiations in 2025, indicating an expected ramp-up in commercial activity.
The company announced a global strategic partnership with Nkure Therapeutics Private Limited to co-develop and co-commercialize CTX112, a next-generation CAR T product candidate, in India. This collaboration expands the geographic reach and development resources for CTX112, which targets CD19 for B-cell malignancies and autoimmune indications. Updates for CTX112 in oncology and autoimmune diseases are expected in mid-2025.
CRISPR Therapeutics also outlined key pipeline updates for 2025, including anticipated updates for its lead in vivo cardiovascular programs, CTX310 and CTX320, in the first half of the year. Updates for CTX131, another CAR T candidate, are also expected in 2025. The company reported a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of December 31, 2024, providing financial stability for its ambitious development plans.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.